| MK-3475 | MK-3475 – PD-1 inhibitor | Recurrent/metastatic colorectal carcinoma (MSI and MSS) and non-colorectal MSI tumors(NCT01876511) | Non-randomized open-label phase II study Primary: 20-week irPFS, 20-week irOR Secondary: OS, RR, DCR | MK-3475 • MK-345 10 mg/kg q2 weeks till progression |